Research published in Lancet Oncology analyzed how the risk of death from Covid-19 varies by tumor subtype and patient demographics.
The U.S. Food and Drug Administration’s approval-review schedule for August includes the Biologics License Application for Bristol Myers Squibb and Juno Therapeutics’ lisocabtagene maraleucel (liso-cel) for relapsed or refractory large B-cell lymphoma after at least two previous therapies.
Genentech’s checkpoint inhibitor Tecentriq combined with chemotherapy failed to hit the mark in a Phase III metastatic triple-negative breast cancer study.
AstraZeneca inked a global development and commercialization deal with Daiichi Sankyo for DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate for multiple cancer types.
San Francisco-based Olema Oncology secured $54 million in an oversubscribed Series B financing round to support the development of the company’s lead breast cancer treatment as well as expand ongoing research and development programs.
Evive Biotech announced that the company’s Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients met the primary and secondary endpoints.
Immunomedics announced that the company’s Phase III study involving Trodelvy met the primary endpoint of progression-free survival, as well as secondary endpoints, in patients with metastatic triple-negative breast cancer who have previously received at least two prior therapies.
In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.
In a Phase III study, Eli Lilly’s Verzenio (abemaciclib) combined with standard adjuvant endocrine therapy met the trial’s primary endpoint of invasive disease-free survival in high-risk breast cancer and significantly reduced the risk of a recurrence of the disease.
The American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually this year due to the COVID-19 pandemic and included hundreds of abstracts, posters and presentations.
